{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:33:31Z","timestamp":1784334811414,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chemotherapy is the main treatment strategy for patients with advanced HER2-negative gastric cancer (GC); yet, many patients do not respond well to treatment. This study evaluated the sensitivity of a mini patient-derived xenograft (MiniPDX) animal model in patients with HER2-negative intermediate-advanced GC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-arm, open-label clinical study, we consecutively recruited patients with HER2-negative advanced or recurrent GC from September 2018 to July 2021.\u00a0Tumor tissues were subjected to MiniPDX drug sensitivity tests\u00a0for screening individualized anti-tumor drugs; appropriate drug types or combinations were selected based on drug screening results. The primary endpoints were progression-free survival (PFS) and safety, and the secondary endpoints were overall survival (OS) and objective response rate (ORR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 17 patients were screened, and 14 eligible patients were included.The median follow-up time was 9 (2\u201334) months. The median PFS time was 14.1 (2\u201334) months, the median OS time was 16.9 (2\u201334) months, ORR was 42.9% (6\/14), and DCR was 92.9% (13\/14). The most common treatment-related adverse events (TRAE) were fatigue (14 (100%)), anorexia (13 (93%)) and insomnia (12 (86%)), and the most common grade 3 or worse TRAE was fatigue (6 (43%)), and anorexia (6 (43%)). The occurrence rate of myelosuppression, nausea and vomiting, abnormal liver enzymes, and other grade 3\u20134 chemotherapy adverse reactions were relatively low, and no grade 5 treatment-related adverse events occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Screening HER2-negative medium-advanced GC\/GJC chemotherapy regimens and targeted drugs based on MiniPDX animal models showed good tumor activity and safety.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-023-00661-y","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:03:03Z","timestamp":1682326983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["OncoVee\u2122-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study"],"prefix":"10.1007","volume":"14","author":[{"given":"Baonan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjie","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenle","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"3","key":"661_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a J Clin. 2021;71(3):209\u201349.","journal-title":"CA: a J Clin"},{"issue":"1","key":"661_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","volume":"17","author":"N Boku","year":"2014","unstructured":"Boku N. HER2-positive gastric cancer. Gastric cancer. 2014;17(1):1\u201312.","journal-title":"Gastric cancer"},{"issue":"9","key":"661_CR3","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann oncol. 2008;19(9):1523\u20139.","journal-title":"Ann oncol"},{"issue":"3","key":"661_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang Y, Feng-Yi F, Xu J, Lee K, Jiao S, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric cancer. 2015;18(3):476\u201384.","journal-title":"Gastric cancer"},{"issue":"1","key":"661_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"C Hudis","year":"2007","unstructured":"Hudis C. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39\u201351.","journal-title":"N Engl J Med"},{"issue":"9742","key":"661_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y Bang","year":"2010","unstructured":"Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010;376(9742):687\u201397.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"661_CR7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10120-022-01298-6","volume":"25","author":"K Bang","year":"2022","unstructured":"Bang K, Cheon J, Park Y, Kim H, Ryu M, Park Y, et al. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric cancer. 2022;25(4):794\u2013803.","journal-title":"Gastric cancer"},{"issue":"12","key":"661_CR8","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1007\/s12094-020-02379-7","volume":"22","author":"Y Yao","year":"2020","unstructured":"Yao Y, Deng R, Liao D, Xie H, Zuo J, Jia Y, et al. Maintenance treatment in advanced HER2-negative gastric cancer. Clin Transl Oncol. 2020;22(12):2206\u201312.","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"661_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"F Wang","year":"2021","unstructured":"Wang F, Zhang X, Li Y, Tang L, Qu X, Ying J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (London, England). 2021;41(8):747\u201395.","journal-title":"Cancer Commun (London, England)"},{"issue":"7","key":"661_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","volume":"17","author":"J Ajani","year":"2019","unstructured":"Ajani J, D\u2019Amico T, Bentrem D, Chao J, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN clinical practice guidelines in oncology. J Nat Compr Cancer Netw. 2019;17(7):855\u201383.","journal-title":"J Nat Compr Cancer Netw"},{"key":"661_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080889","author":"S Okada","year":"2019","unstructured":"Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8080889.","journal-title":"Cells"},{"issue":"1","key":"661_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"G Yoshida","year":"2020","unstructured":"Yoshida G. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13(1):4.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"661_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neo.2020.11.005","volume":"23","author":"M Rivera","year":"2021","unstructured":"Rivera M, Fichtner I, Wulf-Goldenberg A, Sers C, Merk J, Patone G, et al. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. Neoplasia (New York, NY). 2021;23(1):21\u201335.","journal-title":"Neoplasia (New York, NY)"},{"issue":"1","key":"661_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40880-018-0329-5","volume":"38","author":"F Zhang","year":"2018","unstructured":"Zhang F, Wang W, Long Y, Liu H, Cheng J, Guo L, et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun (London, England). 2018;38(1):60.","journal-title":"Cancer Commun (London, England)"},{"key":"661_CR15","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.2147\/CMAR.S276799","volume":"13","author":"Y Huang","year":"2021","unstructured":"Huang Y, Xu J, Li K, Wang J, Dai Y, Kang Y. A novel, personalized drug-screening system for platinum-resistant ovarian cancer patients: a preliminary clinical report. Cancer Manag Res. 2021;13:2849\u201367.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"661_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1177\/10781552221074973","volume":"28","author":"X Zhu","year":"2022","unstructured":"Zhu X, Zhu Y, Chen N, Tang C, Shi J. The drugs screened by OncoVee-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer. J Oncol Pharm Pract. 2022;28(6):1435\u201340.","journal-title":"J Oncol Pharm Pract"},{"key":"661_CR17","first-page":"1987705","volume":"2022","author":"J Wang","year":"2022","unstructured":"Wang J, Huang J, Wang H, Yang W, Bai Q, Yao Z, et al. Personalized treatment of advanced gastric cancer guided by the MiniPDX model. J Oncol. 2022;2022:1987705.","journal-title":"J Oncol"},{"key":"661_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757383","volume":"11","author":"Y Ge","year":"2021","unstructured":"Ge Y, Zhang X, Liang W, Tang C, Gu D, Shi J, et al. OncoVee\u2122-MiniPDX-guided anticancer treatment for gastric cancer patients with synchronous liver metastases: a retrospective cohort analysis. Front Oncol. 2021;11: 757383.","journal-title":"Front Oncol"},{"issue":"10","key":"661_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","volume":"14","author":"J Ajani","year":"2016","unstructured":"Ajani J, D\u2019Amico T, Almhanna K, Bentrem D, Chao J, Das P, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network. 2016;14(10):1286\u2013312.","journal-title":"J Natl Compr Cancer Network"},{"issue":"5","key":"661_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.ccell.2020.08.002","volume":"38","author":"C Li","year":"2020","unstructured":"Li C, Sun Y, Yu G, Cui J, Lou Z, Zhang H, et al. Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell. 2020;38(5):734-47.e9.","journal-title":"Cancer Cell"},{"key":"661_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s42826-020-00045-1","volume":"36","author":"S Cho","year":"2020","unstructured":"Cho S. Patient-derived xenografts as compatible models for precision oncology. Laboratory animal research. 2020;36:14.","journal-title":"Laboratory animal research"},{"issue":"3","key":"661_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","volume":"20","author":"C Fuchs","year":"2019","unstructured":"Fuchs C, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):420\u201335.","journal-title":"Lancet Oncol"},{"issue":"6","key":"661_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick F, Kang Y, Chung H, Salman P, Oh S, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490\u20139.","journal-title":"Lancet Oncol"},{"issue":"5","key":"661_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamaoncol.2016.5580","volume":"3","author":"M Shah","year":"2017","unstructured":"Shah M, Bang Y, Lordick F, Alsina M, Chen M, Hack S, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 2017;3(5):620\u20137.","journal-title":"JAMA Oncol"},{"issue":"2","key":"661_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10637-009-9363-0","volume":"29","author":"C Kim","year":"2011","unstructured":"Kim C, Lee J, Ryu M, Chang H, Kim T, Lim H, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and\/or recurrent advanced gastric cancer. Invest New Drugs. 2011;29(2):366\u201373.","journal-title":"Invest New Drugs"},{"issue":"1","key":"661_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12885-018-4615-z","volume":"18","author":"Y Wang","year":"2018","unstructured":"Wang Y, Cheng X, Cui Y, Hou J, Ji Y, Sun Y, et al. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer. 2018;18(1):702.","journal-title":"BMC Cancer"},{"issue":"10","key":"661_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/CAD.0b013e328314b5ab","volume":"19","author":"H Zhong","year":"2008","unstructured":"Zhong H, Zhang Y, Ma S, Ying J, Yang Y, Yong D, et al. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19(10):1013\u20138.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"661_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/COC.0b013e3181f47ac1","volume":"34","author":"H Luo","year":"2011","unstructured":"Luo H, Wang Z, Wang F, Qiu M, Teng K, Ruan D, et al. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. Am J Clin Oncol. 2011;34(6):555\u201360.","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"661_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-018-0903-9","volume":"78","author":"L Scott","year":"2018","unstructured":"Scott L. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747\u201358.","journal-title":"Drugs"},{"issue":"6","key":"661_CR30","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","volume":"52","author":"MA Kim","year":"2008","unstructured":"Kim MA, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52(6):738\u201346.","journal-title":"Histopathology"},{"issue":"4","key":"661_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/bjc.2013.41","volume":"108","author":"NC Tebbutt","year":"2013","unstructured":"Tebbutt NC, et al. Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer. 2013;108(4):771\u20134.","journal-title":"Br J Cancer"},{"key":"661_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1477-7819-12-115","volume":"12","author":"ZD Zhang","year":"2014","unstructured":"Zhang ZD, et al. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World J Surg Oncol. 2014;12:115.","journal-title":"World J Surg Oncol"},{"key":"661_CR33","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fonc.2019.01308","volume":"9","author":"C Arienti","year":"2019","unstructured":"Arienti C, et al. Epidermal growth factor receptor family and its role in gastric cancer. Front Oncol. 2019;9:1308.","journal-title":"Front Oncol"},{"issue":"2","key":"661_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bcp.2014.06.008","volume":"91","author":"E Rosfjord","year":"2014","unstructured":"Rosfjord E, Lucas J, Li G, Gerber H. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 2014;91(2):135\u201343.","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"661_CR35","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(11):1318\u201325.","journal-title":"Nat Med"},{"issue":"4","key":"661_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc.2016.140","volume":"17","author":"A Byrne","year":"2017","unstructured":"Byrne A, Alf\u00e9rez D, Amant F, Annibali D, Arribas J, Biankin A, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17(4):254\u201368.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"661_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s13304-020-00751-4","volume":"72","author":"R Reddavid","year":"2020","unstructured":"Reddavid R, Corso S, Moya-Rull D, Giordano S, Degiuli M. Patient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review. Updat Surg. 2020;72(4):951\u201366.","journal-title":"Updat Surg"},{"issue":"1","key":"661_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00280-020-04182-1","volume":"87","author":"L Yang","year":"2021","unstructured":"Yang L, Yuan Z, Zhang Y, Cui Z, Li Y, Hou J, et al. MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma. Cancer Chemother Pharmacol. 2021;87(1):125\u201334.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"661_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40880-018-0318-8","volume":"38","author":"M Zhan","year":"2018","unstructured":"Zhan M, Yang R, Wang H, He M, Chen W, Xu S, et al. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun (London, England). 2018;38(1):48.","journal-title":"Cancer Commun (London, England)"},{"issue":"1","key":"661_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0323-y","volume":"38","author":"P Zhao","year":"2018","unstructured":"Zhao P, Chen H, Wen D, Mou S, Zhang F, Zheng S. Personalized treatment based on mini patient-derived xenografts and WES\/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. Cancer Commun. 2018;38(1):1\u20137.","journal-title":"Cancer Commun"},{"issue":"2","key":"661_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.7150\/ijms.68404","volume":"19","author":"S Liu","year":"2022","unstructured":"Liu S, Liang H, Yang Z, Cai C, Wu Z, Wu X, et al. Gemcitabine and XCT790, an ERR\u03b1 inverse agonist, display a synergistic anticancer effect in pancreatic cancer. Int J Med Sci. 2022;19(2):286\u201398.","journal-title":"Int J Med Sci"},{"key":"661_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04403-9","author":"J Xu","year":"2022","unstructured":"Xu J, Gao Y, Luan X, Li K, Wang J, Dai Y, et al. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. Cancer Chemother Pharmacol. 2022. https:\/\/doi.org\/10.1007\/s00280-022-04403-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10294","key":"661_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27\u201340.","journal-title":"The Lancet"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00661-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-023-00661-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00661-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:27:29Z","timestamp":1682328449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-023-00661-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1007\/s12672-023-00661-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"26 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was performed in accordance with the Declaration of Helsinki regarding ethical principles for research involving human tissues. The protocols for our study were approved by the Institutional Review Board of Wuxi Hospital of Traditional Chinese Medicine (Ethical Approval Number 201809001J01-01). The animal study was reviewed and approved by the Institutional Animal care and use Committee(IACUC) Shanghai LIDI Biotech,Co.LTD, and written informed consent was obtained from all patients prior to participation in our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}